Literature DB >> 8398688

Tumourigenesis associated with the p53 tumour suppressor gene.

F Chang1, S Syrjänen, A Tervahauta, K Syrjänen.   

Abstract

The p53 gene is contained within 16-20 kb of cellular DNA located on the short arm of human chromosome 17 at position 17p13.1. This gene encodes a 393-amino-acid nuclear phosphoprotein involved in the regulation of cell proliferation. Current evidence suggests that loss of normal p53 function is associated with cell transformation in vitro and development of neoplasms in vivo. More than 50% of human malignancies of epithelial, mesenchymal, haematopoietic, lymphoid, and central nervous system origin analysed thus far, were shown to contain an altered p53 gene. The oncoproteins derived from several tumour viruses, including the SV40 large T antigen, the adenovirus E1B protein and papillomavirus E6 protein, as well as specific cellular gene products, e.g. murine double minute-2 (MDM2), were found to bind to the wild-type p53 protein and presumably lead to inactivation of this gene product. Therefore, the inactivation of p53 tumour suppressor gene is currently regarded as an almost universal step in the development of human cancers. The current data on p53-associated tumourigenesis are briefly discussed in this minireview.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8398688      PMCID: PMC1968607          DOI: 10.1038/bjc.1993.404

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  108 in total

1.  Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation.

Authors:  P Hinds; C Finlay; A J Levine
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

Review 2.  The molecular genetics of cancer.

Authors:  J M Bishop
Journal:  Science       Date:  1987-01-16       Impact factor: 47.728

3.  SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene.

Authors:  J A DeCaprio; J W Ludlow; J Figge; J Y Shew; C M Huang; W H Lee; E Marsilio; E Paucha; D M Livingston
Journal:  Cell       Date:  1988-07-15       Impact factor: 41.582

4.  Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product.

Authors:  P Whyte; K J Buchkovich; J M Horowitz; S H Friend; M Raybuck; R A Weinberg; E Harlow
Journal:  Nature       Date:  1988-07-14       Impact factor: 49.962

5.  Identification of the p53 protein domain involved in formation of the simian virus 40 large T-antigen-p53 protein complex.

Authors:  T H Tan; J Wallis; A J Levine
Journal:  J Virol       Date:  1986-09       Impact factor: 5.103

6.  The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product.

Authors:  N Dyson; P M Howley; K Münger; E Harlow
Journal:  Science       Date:  1989-02-17       Impact factor: 47.728

7.  Immortalization of rat embryo fibroblasts by the cellular p53 oncogene.

Authors:  B Rovinski; S Benchimol
Journal:  Oncogene       Date:  1988-05       Impact factor: 9.867

8.  Characterization of the in vitro interaction between SV40 T antigen and p53: mapping the p53 binding site.

Authors:  F I Schmieg; D T Simmons
Journal:  Virology       Date:  1988-05       Impact factor: 3.616

9.  A cancer family syndrome in twenty-four kindreds.

Authors:  F P Li; J F Fraumeni; J J Mulvihill; W A Blattner; M G Dreyfus; M A Tucker; R W Miller
Journal:  Cancer Res       Date:  1988-09-15       Impact factor: 12.701

10.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.

Authors:  S J Baker; E R Fearon; J M Nigro; S R Hamilton; A C Preisinger; J M Jessup; P vanTuinen; D H Ledbetter; D F Barker; Y Nakamura; R White; B Vogelstein
Journal:  Science       Date:  1989-04-14       Impact factor: 47.728

View more
  28 in total

1.  Changes in expression of oncogenes and TP53 tumour suppressor gene as biomarkers in head and neck cancers.

Authors:  István Szanyi; Miklós Bauer; Imre Gerlinger; Tamás Járai; Gyula Gobel; László Lujber; Eva Szabadi; Katalin Fehér; Agoston Émber; István Ember; István Kiss
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-12-01       Impact factor: 2.503

2.  Immunoreactivity for p53 and mdm2 and the detection of p53 mutations in human malignant mesothelioma.

Authors:  K Segers; H Backhovens; S K Singh; J De Voecht; M Ramael; C Van Broeckhoven; E Van Marck
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

3.  Histochemical investigation into the molecular mechanisms of malignant transformation in a benign glomus tumour.

Authors:  L Hegyi; G C Cormack; J W Grant
Journal:  J Clin Pathol       Date:  1998-11       Impact factor: 3.411

Review 4.  New plays in the p53 theater.

Authors:  Yael Aylon; Moshe Oren
Journal:  Curr Opin Genet Dev       Date:  2010-11-04       Impact factor: 5.578

5.  RAP80 is critical in maintaining genomic stability and suppressing tumor development.

Authors:  Zhengyu Yin; Daniel Menendez; Michael A Resnick; John E French; Kyathanahalli S Janardhan; Anton M Jetten
Journal:  Cancer Res       Date:  2012-08-15       Impact factor: 12.701

6.  Homozygous and heterozygous p53 knockout rats develop metastasizing sarcomas with high frequency.

Authors:  Ruben van Boxtel; Raoul V Kuiper; Pim W Toonen; Sebastiaan van Heesch; Roel Hermsen; Alain de Bruin; Edwin Cuppen
Journal:  Am J Pathol       Date:  2011-08-18       Impact factor: 4.307

7.  Expression of p53, MDM2 protein and Ki-67 antigen in recurrent meningiomas.

Authors:  M Ohkoudo; H Sawa; M Hara; K Saruta; T Aiso; R Ohki; H Yamamoto; E Maemura; Y Shiina; M Fujii; I Saito
Journal:  J Neurooncol       Date:  1998-05       Impact factor: 4.130

8.  Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma.

Authors:  M Salih Deveci; Güzin Deveci
Journal:  Gastric Cancer       Date:  2007-06-25       Impact factor: 7.370

9.  DNA vaccination with a mutated p53 allele induces specific cytolytic T cells and protects against tumor cell growth and the formation of metastasis.

Authors:  Matjaz Humar; Martina Maurer; Marc Azemar; Bernd Groner
Journal:  J Cancer Res Clin Oncol       Date:  2008-10-10       Impact factor: 4.553

10.  The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein.

Authors:  J Keleti; M M Quezado; M M Abaza; M Raffeld; M Tsokos
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.